View Item 

Show simple item record

p63, CK7, PAX8 and INI‐1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high‐grade tumours of the renal collecting system
dc.contributor.authorCarvalho, Jason Cen_US
dc.contributor.authorThomas, Dafydd G.en_US
dc.contributor.authorMcHugh, Jonathan B.en_US
dc.contributor.authorShah, Rajal B.en_US
dc.contributor.authorKunju, Lakshmi P.en_US
dc.date.accessioned2012-03-16T15:57:19Z
dc.date.available2013-05-01T17:24:43Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationCarvalho, Jason C; Thomas, Dafydd G; McHugh, Jonathan B; Shah, Rajal B; Kunju, Lakshmi P (2012). "p63, CK7, PAX8 and INI‐1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high‐grade tumours of the renal collecting system." Histopathology 60(4). <http://hdl.handle.net/2027.42/90230>en_US
dc.identifier.issn0309-0167en_US
dc.identifier.issn1365-2559en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90230
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherCollecting Duct Carcinomaen_US
dc.subject.otherRenal Medullary Carcinomaen_US
dc.subject.otherUrothelial Carcinomaen_US
dc.subject.otherP63en_US
dc.subject.otherImmunohistochemistryen_US
dc.subject.otherPAX8en_US
dc.titlep63, CK7, PAX8 and INI‐1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high‐grade tumours of the renal collecting systemen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Urologic Pathology, Caris Life Sciences, Irving, TX, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90230/1/j.1365-2559.2011.04093.x.pdf
dc.identifier.doi10.1111/j.1365-2559.2011.04093.xen_US
dc.identifier.sourceHistopathologyen_US
dc.identifier.citedreferenceOzcan A, Shen SS, Hamilton C et al. PAX 8 expression in non‐neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod. Pathol. 2011; 24; 751 – 764.en_US
dc.identifier.citedreferenceEble JNSG, Epstein JI, Sesterhenn IA eds. World Health Organization classification of tumours. Lyon: IARC Press, 2004.en_US
dc.identifier.citedreferenceTokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J. Urol. 2006; 176; 40 – 43; discussion 43.en_US
dc.identifier.citedreferenceShah RB, Bakshi N, Hafez KS, Wood D Jr, Kunju LP. Image‐guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. Hum. Pathol. 2005; 36; 1309 – 1315.en_US
dc.identifier.citedreferenceSrigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin. Diagn. Pathol. 1998; 15; 54 – 67.en_US
dc.identifier.citedreferenceCarvalho JC, Wasco MJ, Kunju LP, Thomas DG, Shah RB. Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C‐kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. Histopathology 2011; 58; 169 – 179.en_US
dc.identifier.citedreferenceYao R, Lopez‐Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007; 27; 3051 – 3058.en_US
dc.identifier.citedreferenceRocca PC, Brunelli M, Gobbo S et al. Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT‐PCR study. Mod. Pathol. 2007; 20; 722 – 728.en_US
dc.identifier.citedreferenceMolinie V, Balaton A, Rotman S et al. Alpha‐methyl CoA racemase expression in renal cell carcinomas. Hum. Pathol. 2006; 37; 698 – 703.en_US
dc.identifier.citedreferenceTretiakova MS, Sahoo S, Takahashi M et al. Expression of alpha‐methylacyl‐CoA racemase in papillary renal cell carcinoma. Am. J. Surg. Pathol. 2004; 28; 69 – 76.en_US
dc.identifier.citedreferenceKobayashi N, Matsuzaki O, Shirai S, Aoki I, Yao M, Nagashima Y. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum. Pathol. 2008; 39; 1350 – 1359.en_US
dc.identifier.citedreferenceGupta R, Balzer B, Picken M et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am. J. Surg. Pathol. 2009; 33; 241 – 247.en_US
dc.identifier.citedreferenceTong GX, Yu WM, Beaubier NT et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod. Pathol. 2009; 22; 1218 – 1227.en_US
dc.identifier.citedreferenceOzcan A, Zhai Q, Javed R et al. PAX‐2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney‐specific cadherin. Arch. Pathol. Lab. Med. 2010; 134; 1121 – 1129.en_US
dc.identifier.citedreferenceKnoepp SM, Kunju LP, Roh MH. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology. Diagn. Cytopathol. 2010, [Epub ahead of print] DOI: 10.1002/dc 21590.en_US
dc.identifier.citedreferenceGupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv. Anat. Pathol. 2008; 15; 127 – 139.en_US
dc.identifier.citedreferenceKunju LP, Mehra R, Snyder M, Shah RB. Prostate‐specific antigen, high‐molecular‐weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am. J. Clin. Pathol. 2006; 125; 675 – 681.en_US
dc.identifier.citedreferenceLangner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R. P63 immunoreactivity distinguishes upper urinary tract transitional‐cell carcinoma and renal‐cell carcinoma even in poorly differentiated tumors. J. Histochem. Cytochem. 2003; 51; 1097 – 1099.en_US
dc.identifier.citedreferenceAlbadine R, Schultz L, Illei P et al. PAX8(+)/p63(−) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am. J. Surg. Pathol. 2010; 34; 965 – 969.en_US
dc.identifier.citedreferenceCheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod. Pathol. 2008; 21; 647 – 652.en_US
dc.identifier.citedreferenceElwood H, Schultz L, Illei PB et al. Immunohistochemical loss of INI‐1expression in collecting duct carcinoma. Mod. Pathol. 2010; 23; 189A.en_US
dc.identifier.citedreferenceAlbadine R, Schultz L, Billis A et al. PAX8(+)/p63(+) immunostaining pattern in renal medullary carcinoma: an intermediate phenotype between urothelial acrcinoma of upper urinary tract and collecting duct carcinoma. Mod. Pathol. 2010; 23; 174A.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2559.2011.04093.x.pdf
Size:
962.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.